Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Torrent Loses US Infringement Battle Over Supernus’ Trokendi XR

Trio Of Originator Patents Protecting Topiramate Brand Will Expire In 2027

Executive Summary

While a US district court sided with Supernus over its patent infringement claims against Torrent, the court’s opinion was sealed due to confidential and proprietary information.

You may also be interested in...

Supernus flies high on FDA OK for Trokendi XR in epilepsy

Investors rallied around shares of Supernus Pharmaceuticals in a big way on 19 August, with the company's stock soaring as high as 26.5% after the US FDA granted its approval for the Rockville, Maryland specialty pharma to market its once-daily extended release formulation of topiramate under the brand-name Trokendi XR as a treatment for patients with epilepsy.

Cosette Launches First US Generic To AbbVie’s Rectiv

Approval of Cosette’s first US generic to Rectiv came with a six-month exclusivity as the originator drug had “inadequate generic competition,” but the company has 75 days to enter the market.

FDA’s New PSG Batch Features GSK’s Inhalers

In its latest batch of product-specific guidances, the FDA released multiple new and revised guidances on inhalers, including several on GSK’s products such as Relenza and the Ellipta trio.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts